Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INTERVIEW: Schroeer on EU regulatory plans for single-use devices

This article was originally published in Clinica

Executive Summary

“A significant shift” is how Peter Schroeer, director of regulatory affairs for EMEA at Johnson & Johnson’s Global Surgery group, described the change made by European Parliament committee ENVI to the European Commission’s original proposal for EU regulations of single-use devices and reprocessing. Clinica’s medtech regulatory affairs editor Amanda Maxwell caught up with Mr Schroeer at the European Medtech Forum, held 9-11 October in Brussels, to find out more about his views on ENVI’s amendments to the proposed rule related specifically to the reprocessing of devices (voted through on 25 September, see www.clinica.co.uk), what it means for industry and what possibility there is for further changes to the rule before Parliaments plenary vote scheduled on 22 October.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT100952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel